Inactive Instrument
Claritas Pharmaceuticals Stock Toronto S.E.
Stocks
KLY
CA1806341071
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 5.37M 3.8M 3.33M 3.08M 2.84M 363M 5.47M 36.77M 14.42M 178M 14.26M 13.95M 616M | P/E 2019 |
-0.74x | P/E 2020 | 0.13x |
|---|---|---|---|---|---|
| Enterprise Value | 6.29M 4.45M 3.9M 3.61M 3.32M 426M 6.41M 43.07M 16.89M 209M 16.7M 16.34M 722M | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
99.74% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 day | +11.11% |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CEO | Chief Executive Officer | 76 | 21/06/2017 |
Victoria Rudman
DFI | Director of Finance/CFO | 58 | 29/06/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CHM | Chairman | 76 | 18/03/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +11.11% | -.--% | - | - | 37 | |
| +0.44% | +1.41% | +4.25% | +10.81% | 50.73B | |
| -1.57% | -3.18% | +379.41% | +593.37% | 39.73B | |
| -0.14% | +0.77% | +29.61% | -5.50% | 34.69B | |
| +1.76% | -1.78% | +20.55% | +53.38% | 33.21B | |
| -0.06% | -4.63% | +2.94% | +31.65% | 26.76B | |
| -1.93% | -1.01% | - | - | 16.8B | |
| -1.49% | -6.18% | +65.50% | +120.53% | 15.37B | |
| +0.78% | +1.16% | +15.53% | +17.32% | 13.78B | |
| -0.97% | -2.83% | +11.09% | -33.29% | 12.85B | |
| Average | +0.77% | -0.98% | +66.11% | +98.53% | 27.1B | |
| Weighted average by Cap. | -0.24% | -0.38% | +81.20% | +124.23% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -21.21M -15M -13.16M -12.19M -11.21M -1.44B -21.62M -145M -56.97M -705M -56.34M -55.11M -2.44B | 4.21M 2.98M 2.61M 2.42M 2.23M 285M 4.29M 28.83M 11.31M 140M 11.18M 10.94M 483M |
| Net Debt | 704K 498K 437K 405K 372K 47.66M 718K 4.82M 1.89M 23.4M 1.87M 1.83M 80.83M | 920K 651K 571K 529K 486K 62.28M 938K 6.3M 2.47M 30.59M 2.44M 2.39M 106M |
Employees
-
Choose MarketScreener 
